November 18-20, 2024 | W Philadelphia Hotel, Philadelphia, PA
Drug Channels Readers Receive 15% Off* with Code 24DGC15.
View the Complete Agenda
Book Your Place
The complex components of gross-to-net management requires cross-functional collaboration in order to effectively develop sound accrual estimates, proper forecasting, optimized pricing and contracting models and accurate financial reporting, all with minimal disruption to market access strategies.
The CPE-accredited Pharma/Biotech GTN Summit is the ideal opportunity to engage in comprehensive sessions for end-to-end GTN excellence, connect with peers to exchange experiences and solutions to common challenges, and participate in interactive discussions that address real-world scenarios to enhance GTN accuracy and efficiency.
Featured Thought-Leaders Leading the Dialogue Include:
- Nancy Bell, Vice President, Head of US Patient Value & Access, Takeda Oncology
- Chris Boneham, Vice President, Market Access US, Y-mAbs Therapeutics
- Prakash Chainani, Vice President – Finance, HR & IT, Lifestar Pharma LLC (a Mankind Group Company)
- George Kappus, Associate Director, M&S Controlling (GtN, Boehringer Ingelheim
- Sherri Cirota, Executive Director, Contracts & Pricing, Alkermes
- Chris Rocco, Senior Director, Market Access Data, Reporting & Analytics, GSK
- Rosalind Davis, Director, Government Pricing & Contracts, CSL Vifor
- Dan Sacchetta, Director Managed Markets Finance- Gross-to-Net, Novartis
- Eckart Beuttenmueller, Director, Gross-to-Net Execution, Bayer
- Kinneret Klein, Executive Director, Commercial Financial Planning & Analysis, Biocryst
- James Engel, Controller, Finance, Collegium Pharmaceuticals
- Brett Nussbaum, Head of Gross to Net Accounting, Novartis
- Timothy Kocses, Executive Director, US Commercial Controller, Bristol Myers Squibb
- Robert Lucchesi, Director, FP&A Sales Reporting & Forecasting, Novo Nordisk
- Funso Olufade, PhD, MBA, Sr. Director – Head, Commercial Finance, Ascendis Pharma
- Amy Ramazio, Contract Forecasting & Analytics Director, GSK US Market Access
- Ranish Singhvi, Vice President, Finance, Accord Healthcare
- Jeffrey Miller, Assistant Vice President & Corporate Controller, Lannett Company
- Bal Ram, SVP Finance, US Operations, Indivior
- Matthew Pellegrini, Sr. Director - Revenue Optimization Contracting & Compliance N.A, Teva Pharmaceuticals
- Michael Domanico, Vice President Finance, Revenue, Sandoz
- Christopher Wang, Corporate Controller, Revance Therapeutics
- Melissa Norton, Assistant Controller, Revenue, Tolmar
- Michael Christiano, Director, Revenue, Ardelyx
Drug Channels subscribers — Save 15% when you reserve your place using the VIP code 24DGC15.
*Offer applies to the current rate and maybe not be applied to existing registrations; additional terms may apply, see website for full details.
The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
No comments:
Post a Comment